GlassScriptPhysician profile
Aaron Thomas Donnell
NPI 1154304848
$13,458.60
in general payments reported to CMS, 2019-2025
32 companies · $1,711 in 2025
The $1,711 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,453 · 2020: $1,368 · 2021: $4,931 · 2022: $1,440 · 2023: $1,492 · 2024: $1,064 · 2025: $1,711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,085 · Honoraria: $175 · Education: $6.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,084.92 |
| Honoraria | $175.00 |
| Education | $6.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $4,211.58 | 2019-2025 | Odactra, Grastek, Ragwitek |
| Astrazeneca Pharmaceuticals LP | $1,566.04 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $1,112.00 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $860.67 | 2019-2025 | Dupixent |
| Covis Pharma Gmbh | $688.26 | 2019-2023 | |
| Genzyme Corporation | $675.99 | 2019-2025 | |
| Csl Behring | $589.08 | 2019-2025 | Haegarda, Andembry |
| Novartis Pharmaceuticals Corporation | $427.32 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $362.92 | 2021-2025 | Orladeyo |
| Optinose US, INC. | $296.34 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $294.62 | 2025 | Neffy |
| Kaleo, INC. | $286.37 | 2019-2023 | Auvi-Q |
| Genentech USA, INC. | $280.30 | 2019-2025 | Xolair |
| Teva Pharmaceuticals USA, INC. | $242.56 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $207.75 | 2020-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $174.03 | 2022-2025 | Adbry |
| Takeda Pharmaceuticals U.S.A., INC. | $169.64 | 2020-2025 | Takhzyro, Hyqvia |
| Amgen INC. | $164.75 | 2022-2025 | Tezspire, Actimmune |
| Shire North American Group INC | $128.75 | 2019 | |
| Pfizer INC. | $126.05 | 2019-2022 | |
| Phadia US INC. | $122.64 | 2022-2025 | Immunocap |
| Seqirus USA INC | $88.58 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Lilly USA, LLC | $82.20 | 2025 | Ebglyss, Taltz |
| Sanofi-Aventis U.S. LLC | $57.48 | 2022 | |
| Hikma Pharmaceuticals USA | $47.92 | 2023-2025 | Ryaltris |
| Biocryst Pharmaceuticals, INC. | $44.82 | 2020 | |
| Organon LLC | $40.48 | 2025 | |
| Uswm, LLC | $36.09 | 2021 | |
| Sanofi Pasteur INC. | $24.02 | 2023 | |
| Circassia INC. | $18.24 | 2019 | |
| Galderma Laboratories, L.P. | $17.99 | 2025 | Nemluvio |
| Nestle Healthcare Nutrition INC. | $13.12 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Donnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.